Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 6, 2008, Pages 1009-1021

  Pacini, Furio ^a   Castagna, Maria Grazia ^a  

^a Department of Internal Medicine   (Italy)

Author keywords

radio iodine; rhTSH; thyroglobulin; thyroid ablation; thyroid cancer

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; THYROTROPIN;

ASPIRATION BIOPSY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DOSAGE SCHEDULE COMPARISON; DOSIMETRY; DRUG APPROVAL; ECHOGRAPHY; EUROPE; FOLLOW UP; HUMAN; HYPOTHYROIDISM; LYMPH NODE METASTASIS; NONHUMAN; NORTH AMERICA; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SYMPTOM; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; IODINE RADIOISOTOPES; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN;

EID: 56649119157     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.014     Document Type: Review

References (68)

1. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 (2006) 2164-2167
2. Leenhardt L., Bernier M.O., Boin-Pineau M.H., et al. Advances in diagnostic practices affect thyroid cancer incidence in France. European Journal of Endocrinology 150 (2004) 133-139
3. Levi F., Randimbison L., Te V.C., et al. Thyroid cancer in Vaud, Switzerland: an update. Thyroid 12 (2002) 163-168
4. Mazzaferri E.L., and Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 86 (2001) 1447-1463
5. Pacini F., Schlumberger M., Dralle H., et al., European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 154 (2006) 787-803
6. Cooper D.S., Doherty G.M., Haugen B.R., et al., The American Thyroid Association Guidelines Taskforce. The American Thyroid Association Guidelines Taskforce Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
7. Schlumberger M.J. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 338 (1998) 297-306
8. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. American Journal of Medicine 97 (1994) 418-428
9. Tubiana M., Schlumberger M., Rougier P., et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55 (1985) 794-804
10. Maxon III H.R., and Smith H.S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology and Metabolism Clinics of North America 19 (1990) 685-718
11. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 79 (1994) 98-105
12. Schlumberger M., and Baudin. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. European Journal of Endocrinology 138 (1998) 249-252
13. Pacini F., Lari R., Mazzeo S., et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clinical Endocrinology 23 (1985) 405-411
14. 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clinical Endocrinology 13 (1980) 107-110
15. Spencer C.A., LoPresti J.S., Fatemi S., et al. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9 (1999) 435-441
16. Dow K.H., Ferrell B.R., and Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7 (1997) 613-619
17. Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 9 (1999) 451-453
18. 131I scintiscans and thyroglobulin testing. Thyroid 6 (1996) 69-73
19. Thotakura N.R., Desai R.K., Bates L.G., et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 128 (1991) 341-348
20. Szkudlinski M.W., Thotakura N.R., Bucci I., et al. Purification and characterization of recombinant human thyrotropin (TSH) isoforms produced by Chinese hamster ovary cells: the role of sialylation and sulfation in TSH bioactivity. Endocrinology 133 (1993) 1490-1503
21. Kashiwai T., Ichihara K., Endo Y., et al. Immunological and biological characteristics of recombinant human thyrotropin. Journal of Immunological Methods 143 (1991) 25-30
22. Weintraub B.D., and Szkudlinski M.W. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 9 (1999) 447-450
23. Huber G.K., Fong P., Concepcion E.S., et al. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. Journal of Clinical Endocrinology and Metabolism 72 (1991) 1328-1331
24. Cole E.S., Lee K., Lauziere K., et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (N Y) 11 (1993) 1014-1024
25. Colzani R.M., Alex S., Fang S.L., et al. The effect of recombinant human thyrotropin (rhTSH) on thyroid function in mice and rats. Thyroid 8 (1998) 797-801
26. Ramirez L., Braverman L.E., White B., et al. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. Journal of Clinical Endocrinology and Metabolism 82 (1997) 2836-2839
27. Torres M.S., Ramirez L., Simkin P.H., et al. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. Journal of Clinical Endocrinology and Metabolism 86 (2001) 1660-1664
28. Lawrence J.E., Emerson C.H., Sullaway S.L., et al. The effect of recombinant human TSH on the thyroid (123)I uptake in iodide treated normal subjects. Journal of Clinical Endocrinology and Metabolism 86 (2001) 437-440
29. Meier C.A., Braverman L.E., Ebner S.A., et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). Journal of Clinical Endocrinology and Metabolism 78 (1994) 188-196
30. Ladenson P.W., Braverman L.E., Mazzaferri E.L., et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 337 (1997) 888-896
31. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 84 (1999) 3877-3885
32. Mariani G., Ferdeghini M., Augeri C., et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biotherapy & Radiopharmaceuticals 15 (2000) 211-217
33. Robbins R.J., Tuttle R.M., Sharaf R.N., et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 (2001) 619-625
34. David A., Blotta A., Bondanelli M., et al. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. Journal of Nuclear Medicine 42 (2001) 1470-1475
35. Vitale G., Lupoli G.A., Ciccarelli A., et al. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clinical Endocrinology 56 (2002) 247-252
36. Pacini F., Molinaro E., Lippi F., et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 (2001) 5686-5690
37. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 88 (2003) 3668-3673
38. Cailleux A.F., Baudin E., Travagli J.P., et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. Journal of Clinical Endocrinology and Metabolism 85 (2000) 175-178
39. Pacini F., Capezzone M., Elisei R., et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. Journal of Clinical Endocrinology and Metabolism 87 (2002) 1499-1501
40. 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 91 (2006) 60-63
41. Mazzaferri E.L., and Kloos R.T. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. Journal of Clinical Endocrinology and Metabolism 87 (2002) 1490-1498
42. Mazzaferri E.L., and Kloos R.T. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. Journal of Clinical Endocrinology and Metabolism 90 (2005) 5047-5057
43. Frasoldati A., Pesenti M., Gallo M., et al. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 1 97 (2003) 90-96
44. Biondi B., Filetti S., and Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice. Endocrinology & Metabolism 1 (2005) 32-40
45. Castagna M.G., Brilli L., Pilli T., et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. Journal of Clinical Endocrinology and Metabolism (2008) 9376-9381
46. Sawka A.M., Thephamongkhol K., Brouwers M., et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 89 (2004) 3668-3676
47. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology 153 (2005) 651-659
48. Haugen B.R. Initial treatment of differentiated thyroid carcinoma. Reviews in Endocrine & Metabolic Disorders 1 (2000) 139-145
49. Robbins R.J., Tuttle R.M., Sonenberg M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11 (2001) 865-869
50. Pacini F., Molinaro E., Castagna M.G., et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 87 (2002) 4063-4068
51. Barbaro D., Boni G., Meucci G., et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nuclear Medicine Communications 27 (2006) 627-632
52. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology 1 (2006) 926-932
53. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 92 (2007) 3542-3546
54. 131I. Journal of Nuclear Medicine 44 (2003) 898-903
55. Luster M., Sherman S.I., Skarulis M.C., et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 1371-1377
56. Hänscheid H., Lassmann M., Luster M., et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine 47 (2006) 648-654
57. Pacini F., Cetani F., Miccoli P., et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World Journal of Surgery 18 (1994) 600-604
58. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism 86 (2001) 4092-4097
59. 131I therapy of thyroid cancer patients. Quarterly Journal of Nuclear Medicine 43 (1999) 324-335
60. Schlumberger M., and Pacini F. Thyroid tumors. 5 edn (2003), editions Nuclèon, Paris pp 3-317
61. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 91 (2006) 2892-2899
62. Robbins R.J., Driedger A., Magner J., and U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16 (2006) 1121-1130
63. Luster M., Lassmann M., Haenscheid H., et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 85 (2000) 3640-3645
64. Lippi F., Capezzone M., Angelini F., et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. European Journal of Endocrinology 144 (2001) 5-11
65. Jarzab B., Handkiewicz-Junak D., Roskosz J., et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. European Journal of Nuclear Medicine and Molecular Imaging 30 (2003) 1077-1086
66. Luster M., Lippi F., Jarzab B., et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 12 (2005) 49-64
67. Luster M., Felbinger R., Dietlein M., et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 15 (2005) 1147-1155
68. Mernagh P., Campbell S., Dietlein M., et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology 155 (2005) 405-414